Kabonib is a brand name for cabozantinib, a tyrosine kinase inhibitor used in oncology to treat various cancers by inhibiting specific enzymes that promote tumor growth and angiogenesis. Kabonib is a critical therapeutic option for patients with certain advanced cancers. Its efficacy in inhibiting tumor growth and progression offers hope for improved patient outcomes. However, due to the potential for significant side effects and drug interactions, it should be prescribed and monitored by healthcare professionals experienced in cancer chemotherapy.

Indications:

• Advanced Renal Cell Carcinoma (RCC): Kabonib is indicated for the treatment of advanced kidney cancer.

• Hepatocellular Carcinoma (HCC): It is used in patients with liver cancer who have previously been treated with other anticancer medications.

• Differentiated Thyroid Cancer: Kabonib is prescribed for locally advanced or metastatic differentiated thyroid cancer that has progressed despite prior therapies.

Cabozantinib targets multiple tyrosine kinases involved in tumor growth and angiogenesis, effectively inhibiting pathways that facilitate cancer cell proliferation and the development of new blood vessels supplying the tumor.

Side Effects:

Common side effects:

• Fatigue

• Nausea

• Diarrhea

• Decreased appetite

• Hypertension (high blood pressure)

• Palmar-plantar erythrodysesthesia (hand-foot syndrome)

Serious adverse effects can occur, such as gastrointestinal perforations, hemorrhage, and thromboembolic events.

Precautions:

• Monitoring: Regular monitoring of blood pressure, liver function tests, and complete blood counts is recommended during treatment.

• Drug Interactions: Kabonib may interact with other medications, including strong CYP3A4 inhibitors or inducers. Inform your healthcare provider of all medications and supplements you are taking.

• Pregnancy and Lactation: Kabonib can cause fetal harm. It is advised to avoid pregnancy during treatment and for at least four months after the last dose. Breastfeeding is not recommended during treatment.

Dosage and Administration:

• Dosage Forms: Kabonib is available in tablet forms of varying strengths, including 20 mg, 40 mg, and 60 mg.

• Administration: The recommended dosage varies based on the type of cancer being treated. It is typically taken orally once daily on an empty stomach, either 1 hour before or 2 hours after a meal. Consistency in the timing of doses is crucial for optimal therapeutic outcomes.